•
Sep 30, 2020
RAPT Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020.
Key Takeaways
RAPT Therapeutics reported a net loss of $14.6 million for the third quarter of 2020, compared to a net loss of $10.0 million for the third quarter of 2019. Research and development expenses increased to $12.9 million, and general and administrative expenses increased to $3.2 million. The company had cash and cash equivalents and marketable securities of $122.8 million as of September 30, 2020.
Reported positive initial data from Phase 1/2 clinical trial evaluating FLX475 in multiple cancer indications.
Advanced FLX475 program and continued enrollment for Phase 1b study of RPT193 in atopic dermatitis.
Expect to read out Phase 1b study of RPT193 in the first half of 2021.
Well positioned for multiple catalysts in 2021.